An EU-funded project is exploring what keeps people committed to a task even when they get bored, distracted or are tempted to stop. The findings could foster productivity-boosting strategies, improve robot-human interactions and even help treat borderline personality disorder.
At the forefront of medicine, gene therapy is based on the insertion of genes into an individual's cells and tissues to treat a disease. Scientists are currently testing several approaches to this experimental technique. One of them, Prof. Seppo Ylä-Herttuala, intends to develop a novel method to treat myocardial ischemia by activating endogenous genes to propel angiogenesis. If successful, he will open a new era in gene therapy.
More than 100 million people worldwide suffer from valvular heart disease, affecting one or more of the heart’s four valves and causing breathlessness, chest pain, dizziness and fainting. If severe valvular heart disease is not properly treated, chances of surviving decrease, especially in the elderly. The only effective therapy is heart valve replacement, which may entail some risks and lead to revision surgeries. What can be done to improve safety and durability of artificial heart valves?
Cell transplantation is a promising new approach for organ regeneration in disease or after injury. To support the differentiation of hepatocytes from stem cells, European researchers developed ex vivo organoids which precisely mimic liver architecture.
'Silent killers'. This is how liver diseases are often described. But, are they really that silent? ERC grantee Mathieu Vinken, a pharmacist by training and worldwide expert in toxicology based at Vrije Universiteit Brussel (VUB), has just proven the contrary.
Dr Joaquim Alves Gaspar is a man of the sea. After many years in the Portuguese Navy, he gave up plans to become an admiral in favour of pursuing a PhD in the History of Cartography. This second career led him to receive an ERC Starting Grant, the first awarded in this budding discipline. With his highly multidisciplinary team (he likes to say that, to work with him, one must be a mathematician fluent in Latin), and the experience obtained as a navigator and navigational instructor, Dr Gaspar hopes to understand how and when the first nautical charts were created. The MEDEA-CHART team is the best place in Portugal, and probably in the world, to study the history of nautical cartography, hoping that this work will provide the domain with its rightful recognition within world history.
Pour la toute première fois, une équipe de scientifiques et des cliniciens dirigée par le chercheur Mickael Tanter, financé par l'UE, a réussi à enregistrer l'activité cérébrale d'un nouveau-né prématuré en phase de repos et lors d'une crise d'épilepsie. À l'aide d'une technologie d'échographie non invasive, cette première mondiale marque un véritable tournant dans le domaine de la recherche et la pratique médicale. Elle offre par ailleurs une vaste gamme d'applications en neuroimagerie et au-delà. L'étude est publiée aujourd'hui dans Science Translational Medicine.
For the first time ever, a team of scientists and clinicians led by the EU-funded researcher Mickael Tanter has managed to record the brain activity of a premature new-born baby during resting and during an epileptic seizure. Using a non-invasive ultrasound technology, this world premiere is a real game changer for researchers and the medical profession, offering a massive range of applications in neuroimaging and beyond. It is published today in Science Translational Medicine.
More than 3.5 million new people are diagnosed with heart failure every year in Europe, with a long-term prognosis of 50% mortality within four years. There is urgent need for more innovative, regenerative therapies with the potential to change the course of the condition.
Cardiovascular diseases (CVD) are a major cause of morbidity and mortality in Europe. Prevention relies on measuring traditional risk factors such as age, gender, hypertension, diabetes, hypercholesterolemia and smoking. However, many individuals, apparently at low-risk, still develop CVD. Improving predictions beyond the traditional risk factors is the challenge undertaken by Prof. Olle Melander.
